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Abstract 
Background: Around 30% of patients with inflammatory bowel disease (IBD) are refractory to current IBD drugs or 
relapse over time. Novel treatments are called for, and low dose Naltrexone (LDN) may provide a safe, easily accessible 
alternative treatment option for these patients. We investigated the potential of LDN to induce clinical response in 
therapy refractory IBD patients, and investigated its direct effects on epithelial barrier function.
Methods: Patients not in remission and not responding to conventional therapy were offered to initiate LDN as a 
concomitant treatment. In total 47 IBD patients prescribed LDN were followed prospectively for 12 weeks. Where 
available, endoscopic remission data, serum and biopsies were collected. Further the effect of Naltrexone on wound 
healing (scratch assay), cytokine production and endoplasmic reticulum (ER) stress (GRP78 and CHOP western blot 
analysis, immunohistochemistry) were investigated in HCT116 and CACO2 intestinal epithelial cells, human IBD intes-
tinal organoids and patient samples.
Results: Low dose Naltrexone induced clinical improvement in 74.5%, and remission in 25.5% of patients. Naltrexone 
improved wound healing and reduced ER stress induced by Tunicamycin, lipopolysaccharide or bacteria in epithelial 
barriers. Inflamed mucosa from IBD patients showed high ER stress levels, which was reduced in patients treated with 
LDN. Cytokine levels in neither epithelial cells nor serum from IBD patients were affected.
Conclusions: Naltrexone directly improves epithelial barrier function by improving wound healing and reducing 
mucosal ER stress levels. Low dose Naltrexone treatment is effective and safe, and could be considered for the treat-
ment of therapy refractory IBD patients.
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Background
Inflammatory bowel disease (IBD) is a chronic inflamma-
tory disorder, which includes Crohn’s disease (CD) and 
ulcerative colitis (UC). The aim of therapy is to induce 
sustained remission, a state of long lasting quiescent dis-
ease. Several drugs exist to induce and maintain remis-
sion, and these drugs are usually prescribed in a step-up 
fashion. Nevertheless, even when using this step-up 
strategy, a subset of patients will fail to reach or maintain 
remission even with the most potent therapies, often due 
to drug intolerance or loss of efficacy. For instance, yearly 
loss of efficacy rates are 13–24% in patients treated with 
anti-tumor necrosis factor α (anti-TNFα) agents [1, 2]. 
In general, such a state of therapy refractoriness occurs 
in 35–60% of all IBD patients and severely limits treat-
ment options, often resulting in surgery or corticosteroid 
dependency [3, 4]. Thus, for this subset of patients, alter-
native treatments remain of continued interest.
The etiology of IBD is complex, with genetic pre-
disposition, an altered microbiome, environmental 
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factors and a weakened epithelial barrier function trig-
gering a chronic mucosal immune response. Targeting 
these different causes with medication is the current 
challenge in IBD treatment. Previous research suggests 
that the endogenous opioid system also plays a role in 
gut immunity [5, 6]. For instance, in IBD patients, the 
µ-opioid receptor (MOR) is overexpressed in mucosal 
T-lymphocytes and monocytes, and ex  vivo stimula-
tion of MOR with the agonist DALDA reduced TNFα 
in mucosal biopsies from IBD patients [7]. In addition, 
DALDA also showed anti-inflammatory responses in 
a mouse model of colitis through inhibition of T cell 
proliferation and cytokine (including TNFα) produc-
tion [8]. Another opioid known to modulate MOR 
responses is Naltrexone. While being a MOR antago-
nist, which blocks endogenous opioid effects when 
used at high concentrations [9], administration of 
low dose Naltrexone (LDN) is postulated to result in 
upregulation of endogenous encephalin and endorphin 
levels and to have a positive modulatory effect on the 
MOR [10, 11]. Thus, the use of LDN in clinical settings 
is gaining interest, with Crohn’s disease, multiple scle-
rosis and fibromyalgia described as potential targets 
for treatment with LDN [12–14]. In both mouse and 
rat models of IBD, LDN alleviated inflammation, in 
part by reducing pro-inflammatory cytokine produc-
tion [15, 16]. Interestingly, we and others have shown 
that endoplasmic reticulum (ER) stress in intestinal 
Paneth cells is one of the contributing factors in IBD 
[17–19], and it was recently reported that Naltrexone 
attenuates inflammation in a mouse liver injury model 
by reducing ER stress [20, 21].
Pilot studies in patients with CD showed a positive 
effect of LDN therapy, with 15 of 17 patients showing 
a clinical response [22]. A subsequent randomized, 
placebo-controlled, double blind study in 34 patients 
found a response rate of 88% in the LDN group ver-
sus 40% in the placebo group after 12  weeks of ther-
apy [23]. In addition LDN was also shown to be safe 
in pediatric IBD patients, and resulted in significantly 
reduced PCDAI scores, with 25% of patients achiev-
ing remission and 67% showing improvement of dis-
ease [24]. The above results suggest that LDN is an 
effective therapy for CD patients, although the exact 
mechanism remains unclear. Based on these promising 
results, patients started to request LDN therapy due to 
its favorable side-effect profile, and at the Erasmus MC 
we decided to start prescribing LDN to therapy refrac-
tory IBD patients with active disease. The aims of this 
study were to assess the clinical effect of LDN and to 
investigate whether LDN has a direct modulatory effect 
on intestinal epithelial barrier function.
Methods
Clinical cohort
A prospective cohort of patients with therapy refractory 
IBD (CD or UC) that started LDN therapy was formed. 
The decision to start LDN therapy was made by the treat-
ing physician, after fully informing the patient of the pos-
sible benefits and drawbacks. All patients were prescribed 
4.5 mg Naltrexone once daily. Patients were instructed to 
administer one dose of LDN before bedtime.
Upon initiation of LDN therapy, patients were fol-
lowed according to usual care at the outpatient clinic, 
with contact (in person or via telephone) after 4, 8 and 
12 weeks. During these visits self-assessed disease activ-
ity and adverse events were recorded. Patients were 
offered endoscopic evaluation and assessment of labora-
tory values after 12 weeks of treatment or at time of dis-
continuation of LDN therapy, whichever occurred earlier. 
This study was approved by the Ethical Committee of the 
Erasmus MC (MEC-2014-656).
Clinical data collection
During the follow-up, demographic data (e.g. age, gen-
der) and IBD related data (e.g. year of diagnosis, con-
comitant and previous IBD related therapies, Montreal 
phenotype classification) were recorded. Additionally, 
where available, data on diagnostic tests, particularly 
endoscopic evaluations, performed prior to the start of 
LDN therapy (with a 1 week window) and during the fol-
low-up period were recorded. All patients that completed 
at least 1 assessment of disease activity were included in 
the cohort.
Clinical outcome measures
Clinical outcomes were based on patient self-assessments 
and outpatient assessments, where available. Patients 
were considered non-responders if no clinical improve-
ment occurred in the first 4  weeks of LDN therapy. 
Patients were considered to have clinical response if 
self-assessed disease activity decreased within the first 
4 weeks of LDN therapy, and lasted for at least 4 weeks 
in total. Of secondary interest were the rates of adverse 
events during LDN therapy. Endoscopy results were 
scored based on the most severe area of inflammation. 
Endoscopic findings in all IBD patients were scored on a 
scale from 0 to 3, representing no inflammation to severe 
inflammation respectively.
Cell lines
Colorectal cancer cell lines HCT116 and CACO-2 
were cultured in Dulbecco’s Modified Eagles Medium 
(DMEM, Lonza, Basel, Switzerland) supplemented with 
100 U/mL penicillin, 100 mg/mL streptomycin (Life tech-
nologies, Bleiswijk, NL) and 10% Fecal Calf Serum (FCS, 
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Sigma-Aldrich, St. Louis, USA). Cells were maintained at 
37 °C in a 5%  CO2 humidified setting.
Organoid culture
Non-inflamed intestinal biopsies were collected from two 
IBD patients undergoing routine endoscopy for their dis-
ease. Organoids were prepared as described [25, 26], see 
Additional file 1 for details.
Cell viability assay
Cell viability was assessed using MTT assays as described 
[27], see Additional file 1: Methods. Each experiment was 
performed twice in triplicate.
Wound healing assay
Wound healing assays were performed as described [28], 
see Additional file  1. The concentration of Naltrexone 
used was based on in  vivo dosages (4.5  mg per ± 60  kg 
bodyweight). Experiments were performed thrice in 
duplicate, with two measure-sites per scratch.
Western blotting
Western blotting was performed as described [29], 
with modifications (see Additional file  1). HCT116 and 
CACO-2 cells were treated with Tunicamycin (2  μM), 
lipopolysaccharide (10  μg/mL LPS) or E. coli (paraffin-
fixed DH5α, 6.25e5/mL) in the presence or absence of 
1 μg/mL Naltrexone. Organoids were treated with LPS in 
the presence or absence of 1 μg/mL Naltrexone. Experi-
ments were performed at least twice.
Immunohistochemistry
FFPE tissue sections were immunohistologically stained 
for GRP78, as described [17, 30], see Additional file  1. 
Antigen retrieval was performed by boiling the slides 
in 600  mL of 10  mM sodium citrate buffer, pH 6.0 for 
15  min. Slides were blocked by incubating in 10% goat 
serum in PBS and incubated with GRP78 antibody (BiP, 
Cell Signaling Technology, Danvers, MA) diluted in 
blocking buffer (1:100) overnight at 4  °C. Rabbit envi-
sion (DAKO, Heverlee, Belgium) was used as secondary 
antibody.
Reverse transcriptase polymerase chain reaction (rt‑PCR)
We used rt-PCR to determine MOR expression on the 
IEC cell lines, using Ribosomal protein (RP2) primers 
were used as control [26], see Additional file 1.
Enzyme linked immunosorbent assay (ELISA)
Cells were plated at 0.2 × 106 per well in 24 wells plates. 
Upon attachment to the plate, cells were treated as 
described in the text and supernatant was harvested after 
24  h. Experiments were performed twice, in duplicate. 
Cytokine levels in supernatants from IECs and patient 
sera were determined by ELISA (Ready-SET-Go!® eBio-
science, San Diego, CA) as per manufacturer’s instruc-
tions. All samples were tested in duplicate in the ELISAs.
Statistical analysis
Continuous variables were reported as medians with 
interquartile range (IQR). Comparisons in continuous 
variables were performed with the Mann–Whitney U 
test. For comparisons of categorical variables, Fisher’s 
exact test was used. For in vitro and ex vivo experiments, 
normality of distribution was assessed with D’agostino 
and Pearson Omnibus normality test. When passing nor-
mality test or when there were insufficient numbers to 
calculate normality, parametric testing was performed, 
otherwise, non-parametric tests were employed. Student 
T-tests were performed for comparisons of two groups. 
For comparisons of more than two groups, ANOVA 
with post hoc testing (Tukey’s multiple comparison 
test) was performed. For all tests, one or two-sided (as 
appropriate) p-values < 0.05 were considered statistically 
significant, graphs show mean ± SEM. Analyses were 
performed using Graphpad Prism 5.0.
Results
Patient characteristics
From July 2010 till August 2014, 47 patients were treated 
with LDN, of which 19 (40.4%) were male and 28 were 
female. Median treatment and follow-up duration after 
start of LDN was 3 months (IQR 3–5 months). Of the 47 
patients, 28 (59.6%) were diagnosed with CD and 19 with 
UC. Three patients had previously undergone surgery (2 
ileocecal resections and 1 subtotal colectomy, all in CD 
patients). The full baseline patient characteristics are 
described in Table 1.
All participants were either steroid dependent or ster-
oid refractory and had previously been treated with 
at least one other drug, and all patients showed clini-
cal signs of disease activity at initiation of LDN therapy. 
Notably, 41 patients (87.2%) had previously received 
at least one anti-TNFα agent, and 19 (40.4%) had been 
treated with two anti-TNFα agents. The 6 patients not 
exposed to anti-TNFα had refused anti-TNFα therapy 
due to fear of possible side effects. The full details on the 
previous and concomitant treatments at start of LDN 
therapy are described in Table 2. Seven patients (14.9%) 
reported adverse events due to LDN, including vivid 
dreams (N = 4), drowsiness (N = 2) and headache (N = 1). 
Two patients discontinued LDN therapy after 2  weeks, 
due to drowsiness. Vivid dream complaints improved 
when LDN was administered in the morning instead of 
at bedtime.
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LDN therapy shows clinical and endoscopic efficacy in IBD 
patients
Of the 47 patients, 35 (74.5%) achieved a clinical 
response. Of those 35 patients, 12 patients had a response 
of at least 3 months (25.5% of total cohort, 8 CD, 4 UC), 
whereas a short-lived (between 4 and 12 weeks) improve-
ment was seen in the remaining 23 patients (48.9% of 
total cohort, 13 CD, 10 UC). There was no statistically 
significant difference between CD and UC patients in 
the number of patients that achieved either response or 
remission (p = 1.000 and p = 0.515 respectively).
The median endoscopic score at baseline amongst all 
patients was 2 (IQR 1.25–2.0). In 12 patients, consecu-
tive endoscopies were performed both at baseline and 
at 12  weeks or at time of relapse, whichever occurred 
earlier. These consecutive endoscopies were performed 
in 6 patients with response (3 CD, 3 UC) and 6 patients 
with remission (1 CD, 5 UC). Between these two groups, 
no significant difference was observed in baseline endo-
scopic score (median 1.67, range 1–3 versus 1.83, range 
0–3 for response and remission respectively p = 0.676). 
However, patients achieving clinical remission had a sig-
nificantly greater improvement in endoscopic score com-
pared to patients not reaching clinical response (median 
change −  1.5, range −  2 to 0 versus 1.0, range 0–2, 
p = 0.005, Fig.  1). Complete endoscopic remission upon 
treatment with LDN was seen in 5 out of 6 patients with 
clinical remission.
Naltrexone improves wound healing in intestinal epithelial 
cell layers
Having shown clinical effect of Naltrexone in patients, 
we next sought to establish whether Naltrexone has 
a direct effect on epithelial cell function. After test-
ing for the presence of MOR (Fig.  2a), we investigated 
the effect of Naltrexone on wound healing in layers of 
HCT116 and CACO2 colonic epithelial cell lines. Fig-
ure  2b shows that scratch wounds inflicted in HCT116 
cell cultures are healed significantly faster when cells are 
treated with Naltrexone as compared to vehicle control 
(p = 0.0001 at t = 24; p = 0.0001 at t = 48). In CACO2 
cells, which migrate much faster than HC116, all wounds 
were healed at t = 48 and the effect of Naltrexone on 
wound size was less clear (t = 24  h, p = 0.085, Fig.  2b, 
right panel). Possibly, the lower MOR expression levels 
observed in CACO2 cells accounts for the lesser effect 
of Naltrexone in this cell line. However, when comparing 
Table 1 Baseline patient characteristics
CD Crohn’s disease, CRP C-reactive protein, IQR inter-quartile range, LDN low dose Naltrexone, UC ulcerative colitis
General characteristics
 Diagnosis, N (%) UC, 19 (40%) CD, 28 (60%) Combined, 47
 Gender (M/F) 10/9 9/19 19/28
 Median age at diagnosis (years, IQR) 31 (27–44.5) 23 (16.8–32.5) 27 (18–39.5)
 Median age at start of LDN (years, IQR) 42 (33.5–52) 35.5 (25.5–53.5) 40 (27.5–52.5)
 Median disease duration at start of LDN (years, IQR) 6.9 (3.2–12.4) 7.8 (3.8–16.5) 7.0 (3.8–13.4)
 CRP mg/L, median (IQR) 7 (2–27) 6 (2–7) 6 (2–9)
 Endoscopic score (median, IQR) 2.0 (1.0–2.0) 2.0 (2.0–2.0) 2.0 (1.25–2.0)
Disease characteristics
 Disease extent or phenotype [montreal classification, % (N)] E1 11% (2) L1 7% (2)
E2 63% (12) L2 32% (9)
E3 26% (5) L3 61% (17)
Table 2 Medical therapies used prior to start of LDN 
and concomitantly with LDN
Steroids refer to any form of corticosteroids. Immunosuppressives refer 
to thiopurines or methotrexate. Other refers to tacrolimus, cyclosporine, 
thioguanine or blinded trial drugs
anti-TNF anti-tumor necrosis factor, CD Crohn’s disease, LDN low dose 
Naltrexone, UC ulcerative colitis
UC, 19 CD, 28 Combined, 47
Prior and concomitant therapies
 Therapies prior to LDN, N (%)
  5-ASA 17 (89%) 14 (50%) 31 (66%)
  Steroids 19 (100%) 28 (100%) 47 (100%)
  Immunosuppressives 18 (95%) 27 (96%) 45 (96%)
  Anti-TNF 16 (84%) 25 (89%) 41 (87%)
  Other 5 (26%) 2 (7%) 8 (15%)
 Concomitant therapies at start of LDN, N (%)
  5-ASA 7 (37%) 3 (11%) 10 (21%)
  Steroids 6 (32%) 18 (64%) 24 (51%)
  Immunosuppressives 8 (42%) 9 (32%) 17 (36%)
  Anti-TNF 5 (26%) 3 (11%) 8 (17%)
  Other 1 (5%) 2 (7%) 3 (6%)
  None 4 (21%) 7 (25%) 11 (23%)
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the migrated distance of cells, it was evident that Naltrex-
one stimulated epithelial cell migration, in both HCT116 
(361 ± 24 vs 656 ± 52 pixels, p = 0.085) and CACO2 
(465 ± 26 vs 310 ± 50 pixels, p = 0.0083, Fig.  2c). This 
effect of Naltrexone on wound healing was not due to an 
increased cellular proliferation, as total viable cell num-
bers were not affected by Naltrexone up to a concentra-
tion of 100 μg/mL (Additional file 2: Figure S1A–C).
Naltrexone does not affect interleukin 8 (IL‑8) cytokine 
levels in epithelial cells and patient sera
In vivo, epithelial cells produce an array of cytokines in 
response to inflammatory stimuli, which in turn can 
attract immune cells and perpetuate inflammation in IBD 
patients. We therefore investigated whether cytokine pro-
duction by epithelial cells is directly affected by Naltrex-
one. Cells were stimulated with bacteria in the absence 
or presence of Naltrexone, and supernatants were tested 
for the presence of the pro-inflammatory cytokines IL-6, 
IL-8 and TNFα after 24 h. As shown in Fig. 3, treatment 
of cells with bacteria significantly increased IL-8 pro-
duction in both HCT116 and CACO2 cells (44 ± 4 to 
92 ± 14 pg/mL in HCT116, p = 0.0001, Fig. 3a and 17 ± 1 
to 25 ± 3  pg/mL in CACO2, p = 0.0001, Fig.  3b). How-
ever, neither basal levels nor bacteria-stimulated levels of 
IL-8 were significantly affected by Naltrexone treatment. 
IL-6 and TNFα levels were undetectable (not shown).
Fig. 1 Changes in individual endoscopic inflammation scores 
values. The change in endoscopic score value for patients in clinical 
remission after week 12 and patients not in clinical remission after 
week 12 are displayed. Each dot represents an individual. The 
horizontal line represents the group median. The difference in 
group medians is statistically significant (− 1.5 versus 1.0, for clinical 
remission and not in clinical remission respectively, p = 0.005)
Fig. 2 Naltrexone improves epithelial wound healing. a Expression of the μ-opioid receptor (MOR) was tested by rt-PCR, using -RT (i.e. RNA) 
controls. Ribosomal protein 2 (RP2) was used as cDNA quality control. b HCT116 (left panel) and CACO2 (right panel) cultures were scratched in 
the presence or absence of 1 μM Naltrexone (NTX), and wounds were photographed at t = 0, 24 and 48. Mean percentage wound size of three 
independent experiments is shown. c Migration of wound edges at t = 24 in pixels presented as mean of three experiments
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Next we tested whether IL-8 or TNFα systemic lev-
els in patients were modulated by Naltrexone treat-
ment in  vivo. Paired serum samples (before and after 
initiation of treatment) were available of 7 patients, 3 
responders and 4 non-responders. IL-8 was detected in 
6 patients (Fig. 3c), whereas TNFα could be measured 
in serum from 5 out of 7 patients (Fig.  3d). No con-
sistent up or down modulation of either IL-8 or TNFα 
was observed, nor were there significant differences 
in these cytokine levels between responders and non-
responders to Naltrexone (Fig.  3e, f ). Together, these 
data suggest that Naltrexone does not positively impact 
on inflammation through modulation of intestinal epi-
thelial cell cytokine production.
ER stress is intestinal epithelium is reduced by Naltrexone
As ER stress in the mucosa has been associated with 
the development of IBD, and Naltrexone was previously 
shown to reduce ER stress-induced inflammation in a 
model of liver damage, we next investigated whether 
Naltrexone has a direct effect on ER stress in intestinal 
epithelium. ER stress was chemically induced in intes-
tinal epithelial cell lines by Tunicamycin (Fig.  4a and 
Additional file 3: Figure S2), as demonstrated by a strong 
upregulation of the ER stress marker GRP78. Interest-
ingly, Naltrexone was able to reduce these levels in both 
cell lines. Chemical stimulation of cells with Tunicamy-
cin causes inhibition of the UDP-N-acetylglucosamine-
dolichol phosphate N-acetylglucosamine-1-phosphate 
Fig. 3 Naltrexone does not affect IL-8 levels in epithelial cell lines and patient sera. Stimulation of HCT116 (a) and CACO2 (b) cell layers for 24 h with 
bacteria results in significantly increased IL-8 levels in culture supernatants as determined by ELISA. Co-treatment with 1 μg/mL Naltrexone does not 
affect basal levels or bacteria-induced levels of IL-8 production in these cell lines. c–f Serum from patients was taken before low dose Naltrexone 
(NTX) treatment, and 3 or 6 months into treatment. IL-8 was detectable in 6 of 7 patients c by ELISA, whereas TNFα was detectable in 5 patients (d). 
There was no significant difference in the mean IL-8 (e) or TNFα (f) levels between responders and non-responders to low dose Naltrexone
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transferase (GPT) and subsequent accumulation of 
unfolded glycoproteins in the ER; a non-physiological 
process likely to result in much higher ER stress lev-
els than are probable in vivo. To investigate ER stress in 
a more physiologically relevant setting, we incubated 
intestinal epithelial cells with bacteria (representative 
examples shown in Fig.  4b and Additional file  3: Fig-
ure S2A). A significant upregulation of GRP78 expres-
sion was observed in HCT116 cells treated with E. coli 
(0.065 ± 0.007 to 0.097 ± 0.01, p = 0.0025, Fig. 4b), which 
again was significantly reduced by co-treatment of cells 
with Naltrexone (0.076 ± 0.005, p = 0.0025). In CACO2 
cells, Naltrexone diminished bacteria-induced GRP78 
expression in three out of three experiments, although 
this did not reach statistical significance as bacteria-
induced ER stress was low in these cells (Additional file 3: 
Figure S2A). In order to further confirm ER stress path-
way activation with a different physiological stimulus, we 
Fig. 4 ER stress in epithelial cell lines is decreased by Naltrexone. a ER stress was induced in HCT116 cells by treatment with 2 μM Tunicamycin 
(Tuni), resulting in an upregulation of GRP78 expression levels as detected by Western Blot analysis. Co-treatment of cells with 1 μg/mL Naltrexone 
(NTX) reduces the amount of Tunicamycin-induced GRP78 expression. Upper graph: mean densitometry values of two independent experiments, 
GRP78 expression is corrected for Actin, to control for equal loading. Representative example is shown in the bottom panels. b Treatment of HCT116 
cells with bacteria results in a significant upregulation of GRP78 expression as detected by Western blot analysis, which is reduced by co-treatment 
cells by treatment of cells with 1 μg/mL Naltrexone. Mean densitometry values of four independent experiments is shown. c Treatment of HCT116 
cells with LPS results in a significant upregulation of CHOP expression as detected by Western blot analysis, which is reduced by co-treatment cells 
by treatment of cells with 1 μg/mL Naltrexone. Mean densitometry values of three independent experiments is shown. d Treatment of organoids 
with LPS results in a significant upregulation of GRP78 expression as detected by Western blot analysis, which is reduced by co-treatment cells 
by treatment of cells with 1 μg/mL Naltrexone. Mean densitometry values are shown of experiments performed on organoids derived from two 
individual donors, with two independent experiments each
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also induced ER stress in HCT116 cells with lipopoly-
saccharide and investigated expression levels of CHOP, 
a downstream target of the ER stress pathway. Figure 4c 
shows that CHOP levels induced by LPS were reduced 
by co-treatment with Naltrexone (1.315 ± 0.592 to 
0.801 ± 0.710, p = 0.027). Again, the effect was less clear 
for CACO2 cells (Additional file 3: Figure S2C).
While cell lines are an easy and common model system 
to study epithelial cell function, such cell lines may show 
different cellular effects due to transforming mutations. 
We therefore generated organoids from colonic biopsies 
from two IBD patients, representing IBD epithelial tissue. 
Stimulation of these organoids with LPS again induced 
GRP78 expression (4 out of 4 experiments), and ER 
stress levels were reduced by co-treatment of organoids 
with Naltrexone (Fig.  4d, 1.734 ± 0.473 to 1.017 ± 0.698, 
p = 0.046). Together, these data imply that ER stress in 
intestinal epithelial cells is alleviated by Naltrexone.
Next, we investigated intestinal ER stress in patients 
treated with LDN. Intestinal tissue biopsies were avail-
able in 13 patients prior to treatment and in 5 patients 
3 months into treatment, with 3 paired samples. Sections 
were stained for GRP78 (for specificity of the staining, 
see Additional file 4: Figure S3). High levels of ER stress 
were observed in both the inflamed intestinal lamina pro-
pria and crypts from IBD patients (Fig. 5a). GRP78 levels 
decreased upon NTX treatment, most noticeably in the 
lamina propria, (1.14 ± 0.5 vs 0.8 ± 0.5 for lamina propria 
and 0.9 ± 0.4 vs 0.7 ± 0.6 for crypts) although statistical 
significance was not reached because of low patient num-
bers (Fig. 4b). However, in the 3 paired samples available, 
NTX treatment reduced interstitial ER stress (Fig.  4c, 
and examples in Fig. 4d). In toto, these data suggest that 
Naltrexone has a direct effect on ER stress as measured 
by GRP78 expression in intestinal mucosa.
Fig. 5 High ER stress in mucosa from IBD patients is reduced by low dose Naltrexone treatment. a Example of GRP78, showing high ER stress 
marker expression in crypts as well as lamina propria. b GRP78 intensity was scored in lamina propria and crypts from biopsies taken from 13 
patients before start of low dose Naltrexone and 5 patients 3 months into treatment. Lower levels of GRP78 expression were observed in lamina 
propria, although this did not reach statistical significance. c Paired biopsies were available from three patients. All three showed reduction of 
GRP78 expression in the lamina propria upon treatment with low dose Naltrexone. d Two paired samples are shown. Patient A was a non-responder, 
Patient B did show clinical response to low dose Naltrexone
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Discussion
In this study, therapy refractory IBD patients receiv-
ing LDN showed clinical improvement in 74.5% of all 
patients and long-lasting clinical remission of in 25.5%. 
Furthermore, most patients achieving clinical remission 
also showed endoscopic improvement. The response 
and remission rates in this study appear slightly lower 
than the rates found in previously published studies 
(response rates of 88–89% and remission rates of 30–67% 
[22, 23]). These differences might be explained by differ-
ences in patient population, as the patients in our cohort 
had more severe disease, as reflected by the differences 
in previous drug exposure. Furthermore, the sample size 
of the previous studies was small, with only 17 and 18 
patients receiving Naltrexone in the pilot study and the 
placebo controlled study, respectively. No serious adverse 
events were reported in the current study. Interestingly, 
we also found no elevated liver enzymes in our cohort, 
whereas previous studies found such abnormalities in 
1.8–11.1% of patients treated with Naltrexone [22, 23]. 
Thus, our data suggest that LDN is safe and effective in 
the treatment of conventional therapy-refractory IBD 
patients.
While the potential benefit of Naltrexone treatment 
for IBD is becoming clear, the underlying mechanisms 
and the general role of the opioid system in IBD have so 
far received very little attention. An increased expres-
sion of MOR in mucosal immune cells has been shown, 
and one possible function of this upregulation may be 
compensatory pain management. Pro-inflammatory Th1 
and Th17 cells produce enhanced levels of endogenous 
opioids during colitis in mice [31], which suppress pain 
signals during chronic mucosal inflammation [32]. As 
such, it is conceivable that part of the remission in LDN 
treated patients is a result of a general improvement of 
well-being. Interestingly, antagonists of the nociceptor 
receptor (involved in pain sensation) also reduced intes-
tinal pro-inflammatory cytokine profiles and amelio-
rated DSS colitis in mice, suggesting that blocking pain 
sensors has a direct immune-modulatory effect [33]. 
Intriguingly, it has recently been shown that the opioid 
inactive (+)-isomers of Naltrexone inhibit lipopolysac-
charide-induced Toll like Receptor 4 (TLR4) signaling, a 
bacterial-induced inflammatory pathway contributing to 
IBD [34, 35]. It is as yet unclear whether the Naltrexone 
preparations currently used in patients (and as bought 
for in vitro experiments) contain this opioid inactive iso-
form, but it is at least theoretically possible that some of 
the beneficial effects observed in the current study are 
not regulated by MOR, but rather by inhibition of TLR 
signaling. Furthermore, in addition to MOR, Naltrexone 
also has weak affinity for the κ and δ opioid receptors, 
and it is conceivable that some of the observed effects 
occur through these receptors.
The limited studies performed so far on the mechanis-
tic effect of Naltrexone have mainly focused on immune 
cells. However, our study suggests that Naltrexone can 
also have direct beneficial consequences on epithelial 
barrier cells, by stimulating wound healing. These data 
are in accordance with the improved in vivo wound heal-
ing observed upon Naltrexone treatment in both IBD 
patients and diabetic mice [36]. However, while the effect 
of Naltrexone on wound healing in skin was shown to 
be a result of increased fibroblast proliferation [37], our 
in vitro model suggests that wound healing of intestinal 
epithelial barriers is modulated by improved migration 
rather than proliferation.
Other studies investigating the potential mechanism 
of LDN on inflammation have focused on immune cell 
cytokine production. Elevated TNFα, IL-6 and IL-12 lev-
els have been reported to be reduced by Naltrexone in 
chemically induced mouse colitis models [15, 16]. In con-
trast, others have found that LDN enhances dendritic cell 
maturation and stimulates their TNFα and IL-12 produc-
tion, whereas in the current study, no effect of Naltrex-
one on either epithelial induced IL-8 production or IL-8 
and TNFα serum levels in IBD patients was observed. 
However, it should be noted that not all cytokines could 
be detected in our system, and it is possible that other 
cytokines, which were not studied here, are affected.
We and others have previously shown that patients 
carrying gene variants associated with development of 
IBD demonstrate increased mucosal ER stress and bacte-
rial persistence, suggesting that intestinal ER stress con-
tributes to IBD pathology [19, 38–40]. The cell type that 
appeared most affected, even in non-inflamed mucosa, 
were the Paneth cells, specialized anti-microbial peptide 
producing cells [17]. We now show that during inflam-
mation, not only Paneth cells, but also other crypt and 
lamina propria cells show increased ER stress, which 
may reflect a general cellular stress response in the pres-
ence of pro-inflammatory cytokines or bacteria. Indeed, 
we demonstrate that stimulation of intestinal epithelial 
cells with bacteria or LPS triggers a significant upregula-
tion of the ER stress marker GRP78. However, not all cell 
lines showed this effect, which may be a reflection of the 
genetic IBD risk factors present in these cell lines. Nev-
ertheless, ER stress in both cell lines as well as organoids 
derived from IBD patients was reduced by treatment with 
Naltrexone, as were lamina propria GRP78 levels in biop-
sies from patients treated with Naltrexone, although this 
did not correlate with clinical response in all cases. Inter-
estingly, genetic variants of the MOR gene OPRM1 affect 
response to high doses of NTX, however to what extent 
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they may play a role in clinical and molecular response in 
IBD patients is as yet unclear [41].
Conclusion
In conclusion, our study provides additional insight into 
the mechanism of action of Naltrexone in intestinal 
inflammation, showing a direct effect of this opioid on 
intestinal epithelial wound healing and ER stress reduc-
tion. The clinical results are promising, and particularly 
given the low frequency and relative beneficial nature of 
side-effects, the use of LDN in therapy refractory IBD 
patients seems warranted. Future clinical research may 
also focus on the use of LDN earlier in the IBD treatment 
pyramid.
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